Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 17, 2010
Last updated: April 14, 2015
Last verified: April 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)